Figure S1. WT naive CD4⁺T cells were CFSE labeled and then stimulated with irradiated splenocytes (1:5), anti-CD3e (1 μ g/mL), and anti-CD-28 (1 μ g/mL), cultured in media containing 5 ng/mL IL-2, 20 μ g/mL anti-IL-4, and 20 μ g/mL anti-IFN γ and treated with either DMSO or 1 μ M GSI. On day 5, cells were washed, restimulated, and cells previously cultured in DMSO were either replated in DMSO or 1 μ M GSI, while cells previously cultured in GSI were maintained in GSI. (A) FACS analysis of cell proliferation on day 3 post-activation. (B) Cell numbers on days 3, 5, and 7 post-activation. (C) FACS analysis of CD69 expression on cells days 5 and 7 post-activation. Data are represented as mean +/- SEM. Related to Figure 2.

Figure S2. (A) WT naive CD4⁺ T cells were CFSE labeled and then stimulated with irradiated splenocytes (1:5), anti-CD3e (1 µg/mL), and anti-CD-28 (1 µg/mL), cultured in media containing 5 ng/mL IL-2, 20 µg/mL anti-IL-4, and 20 µg/mL anti-IFNy and treated with either DMSO or 1 μ M GSI. RNA was harvested on day 5 post-activation and analyzed by gPCR. (B) YFP^{fl/fl} or DNMAML^{fl/fl} CD4⁺ T cells were Tat-cre treated and rested for 24 hours in media containing 100 ng/mL IL-7. Naive CD4⁺ T cells were then FACS sorted and stimulated with irradiated splenocytes (1:5), anti-CD3e (1 µg/mL), and anti-CD-28 (1 µg/mL), and cultured in media containing 5 ng/mL IL-2, 20 µg/mL anti-IL-4, and 20 µg/mL anti-IFNg. After 5 days, RNA was harvested and analyzed by gPCR. (C) YFP^{FL/FL} or DNMAML^{FL/FL} CD4⁺ T cells were Tat-cre treated and rested for 24 hours in media containing 100 ng/mL IL-7. Naive CD4⁺ T cells were then FACS sorted, labeled with CFSE, and stimulated as above under neutral conditions. After 3 days, cell proliferation was measured by FACS. (D) FACS sorted, Tat-cre treated, naïve CD4⁺ T cells from either YFP^{FL/FL} or DNMAML^{FL/FL} mice were stimulated as above under neutral conditions. Apoptosis and cell death were measured on day 5 by FACS using Annexin-V and DAPI staining. Data are represented as mean +/- SEM. Related to Figure 3.

Table S1. List of qPCR primers used. Related to Figures 3 and 4.

Table S2. List of ChIP qPCR primers used. Related to Figures 3 and 4.





4	5'-CATGGAGCTGCAGAGACTCTTTC-3'
	5'-TCCAGGAAGTCTTTCAGTGATGTG-3'
lfng	5'-CACGGCACAGTCATTGAAAG-3'
	5'-GCTGATGGCCTGATTGTCTT-3'
Gata3 exon 1a	5'-CTGGCTGAGATGCAGTGAAG-3'
	5'-GCTCAGAGACGGTTGCTCTT-3'
Gata3 exon 1b	5'-AGCTGTCTGCGAACACTGAG-3',
	5'-GCTCAGAGACGGTTGCTCTT-3'
Tbx21	5'-TCAACCAGCACCAGACAGAGA-3'
	5'-CCACATCCACAAACATCCTGTAAT-3'
Rorc	5'-CCGCTGAGAGGGCTTCAC-3'
	5'-TGCAGGAGTAGGCCACATTACA-3'
ll17a	5'-TCCACGTCACCCTGGACTCT-3'
	5'-CATGTGGTGGTCCAGCTTTC-3'

Suplementary Table 1: Quantitative PCR primer sequences

Suplementary Table 2: ChIP primer sequences

<i>ll4</i> HS-V	5'-TTGAAGTAGCCCTCCTCACGATCA-3'
	5'-AGCCTCCAGACAAATTGGTGAGTG-3'
Ifng CNS-22	5'-CAGGAAGGAGATGGGAAGTCA-3'
	5'-CTGTCTTTTGACAATGAGCAGAAAT-3'
Gata3 exon 1a	5'-TTCCACAGGGCAGTGTCATT-3'
	5'-CACACAAACCGCACATCAGA-3'
Tbx21	5'-AGTCAGCCCTGGGACTCTGA-3'
	5'-TTGGAAGCTGTCTCCCAAGAA-3'
Nanog	5'-GGCTGCCTCTCCTCGCCCT-3'
	5'-GTGCACACAGCTGGGCCTGA-3'